Zogenix–HBM: investment, 202201 investment existent at time of $1.76b cash tender offer for Zogenix by UBS |
2022-01-19 |
Ymmunobio–Yumab: cancer antibody drug, 202206– collab €na optimisation of CEACAM antibodies by Yumab |
2022-06-16 |
XtalPi–Swiss Investment Group: investment, 202009 financing round Series C totalling $318.8m incl existing + co-investor SIG |
2020-09-28 |
XtalPi–Swiss Investment Group: investment, 201810 financing round Series B-1 extension totalling $46m incl co-investor SIG |
2018-10-24 |
Xpand Biotechnology–Kuros: investment, 201612 merger acquisition of Xpand Biotechnology BV by Kuros Biosciences AG for up to 2.105m new Kuros shares |
2016-12-19 |
Xigen–Instinctif Partners: public relations, 201701 service existent by Instinctif Partners |
2017-01-05 |
Xencor–Selexis: cell line development, 201611– supply service strategic agreem for SUREtechnology for developm of multi-specific antibodies |
2016-11-03 |
Xencor–Selexis: cell line development, 2011– supply service agreem for SUREtechnology for developm of multi-specific antibodies |
2011-01-01 |
Xencor–JSR Corp: cell line development, 201802– four commercial licenses to use Selexis’ SUREtechnology for developm of bispecific antibodies |
2018-02-26 |
Xeltis–SEVERAL: investment, 201711 financing round Series C €45m led by a global strategic investor + incl Ysios Capital + LSP + Kurma Partners et al |
2017-11-15 |
Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research |
2019-02-06 |
Waters–Andrew Alliance: automated liquid handling technology, 201706– collab co-marketing semi-automated sample prep solution |
2017-06-01 |
Voluntis–Debiopharm: investment, 202011 capital increase totalling €5.93m incl €3.92m from new + lead investor Debiopharm Innovation Fund |
2020-11-23 |
Vividion Therapeutics–Nextech: investment, 201904 financing round Series B totalling $82m incl new + lead investor Nextech Invest |
2019-04-30 |
Vivet Therapeutics–Roche: investment, 201705 financing round Series A totalling €37.5m incl co-investor Roche Venture Fund |
2017-05-04 |
Vivet Therapeutics–Novartis: investment, 201705 financing round Series A totalling €37.5m incl co-lead investor Novartis Venture Fund |
2017-05-04 |
Visus Therapeutics–Wille Finance: investment, 202103 financing round Series A totalling $36m incl investor Wille AG |
2021-03-09 |
Vifor Pharma–Evotec: drug RnD, 201911– collab establishment 50/50 joint venture for nephrology treatments using NURTuRE biobank + PanHunter s/w |
2019-11-06 |
Vifor Pharma–CSL: investment, 202112– cash tender offer CHF10.9b ($11.7b) at CHF167/share ANNOUNCED |
2021-12-14 |
Vertex–CRISPR Therapeutics: CRISPR technology, 202303– license non-excl $100m upfront + $230m milestones + royalties CRISPR/Cas9 for cell therapies |
2023-03-27 |
Vertex–CRISPR Therapeutics: CRISPR technology, 201906– collab expansion $175m upfront + $825m milestones CRISPR for DMD + DM1 gene editing products |
2019-06-06 |
Versantis–SEVERAL: investment, 201909 financing round Series B CHF16m led by Swisscanto Invest by ZKB |
2019-09-18 |
Versantis–SEVERAL: investment, 201703 financing round Series A CHF4.4m led by Redalpine Venture Partners |
2017-03-29 |
Versantis–Halsin Partners: public relations, 201909 service existent by Halsin Partners |
2019-09-17 |
Versantis–Genfit: investment, 202209– acquisition CHF40m upfront + CHF65m milestones + 1/3 of net proceeds of eventual PRV |
2022-09-19 |
Versameb–SEVERAL: investment, 201910 seed C financing round CHF6.4m bringing total capital raised to CHF11.8m |
2019-10-17 |
Versameb–SEVERAL: investment, 201812 colsing of seed B financing round brining total capital raised to date to CHF5.3m |
2018-12-18 |
Vera Therapeutics–Merck (DE): atacicept, 202011– license for 10% equity in Vera + €605m milestones + royalties |
2020-11-09 |
Vector BioPharma–Versant Ventures: investment, 202208 company emerges with $30m Series A commitment from Versant Ventures |
2022-08-10 |
VectivBio–WPP: public relations, 202001 service existent by Glover Park Group |
2020-01-07 |
VectivBio–Versant Ventures: investment, 202001 1st financing round totalling $35m incl Versant Ventures |
2020-01-07 |
VectivBio–Tekla Capital: investment, 202001 1st financing round totalling $35m incl Tekla Healthcare Investors |
2020-01-07 |
VectivBio–SEVERAL: investment, 202104 IPO $127.5m+$19.125m with 7.5m+1.125m ordinary shares at $17/share at Nasdaq Global Market |
2021-04-08 |
VectivBio–SEVERAL: investment, 202010 crossover financing $110m from existing + new investors |
2020-10-15 |
VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. |
2020-01-07 |
VectivBio–OrbiMed: investment, 202001 1st financing round totalling $35m incl OrbiMed |
2020-01-07 |
VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings |
2020-01-07 |
VectivBio–Kreos Capital: credit, 202203– loan facility up to $75m with minimum draw down of $10m |
2022-03-30 |
VectivBio–Ironwood: investment, 202305–202306 acquisition $1b net of cash/debt cash tender offer at $17/share |
2023-05-21 |
VectivBio–France (govt): investment, 202001 1st financing round totalling $35m incl Bpifrance + Inserm Transfer Initiative |
2020-01-07 |
VectivBio–Forbion: investment, 202305 existent shareholder Forbion |
2023-05-01 |
VectivBio–Cowen: investment, 202001 1st financing round totalling $35m incl Cowen Healthcare Investors |
2020-01-07 |
Vaximm–NEC: investment, 201911 equity investment by NEC in connection with collab + option agreem |
2019-11-12 |
Vandria–SEVERAL: investment, 202312 emerges from stealth with financing round Series A CHF18m led by +ND Capital |
2023-12-14 |
Vandria–OTHER: investment, 202312 emerges from stealth with financing round Series A totalling CHF18m incl small syndicate of HNW private investors |
2023-12-14 |
Vandria–+ND Capital: investment, 202312 emerges from stealth with financing round Series A totalling CHF18m incl lead investor +ND Capital |
2023-12-14 |
Valo Health–HBM: investment, 202101 financing round Series B totalling $190m incl new + co-investor HBM Healthcare Investments |
2021-01-11 |
Valerius Biopharma–Catalent: contract manufacturing, 201805– collab cell line developm + manufacturing of speciality biosimilars using GPEx technology |
2018-05-14 |
Vaderis Therapeutics–Medicxi: investment, 2020 Series A financing CHF18m from Medicxi |
2020-01-01 |
Vaderis Therapeutics–Almac: allosteric AKT inhibitors, 202004 acquisition portfolio of allosteric AKT inhibitors from Almac Discovery Ltd by Vedaris |
2020-04-01 |
Upstream Bio–HBM: investment, 202206 financing round Series A totalling $200m incl co-investor HBM Healthcare Investments |
2022-06-02 |
Univ Florence–Bruker: NMR spectrometer, 201908– supply expected first customer for new 1.2 GHz NMR spectrometer |
2019-08-26 |
UbiSim–Labster: investment, 202110– acquisition of UbiSim by Labster SIGNED |
2021-10-14 |
Twist Bioscience–Genedata: bioinformatics, 202002 supply existent Twist is existing customer of Genedata |
2020-02-26 |
Twentyeight-Seven–Novartis: investment, 201809 financing round Series A totalling $65m incl co-lead investor NVF |
2018-09-06 |
Tusk Therapeutics–Roche: investment, 201809 acquisition for €70m cash + €585m milestones with some assets spun out into Black Belt Therapeutics |
2018-09-28 |
Turnstone Biologics–Scailyte: biomarker discovery, 202303– collab biomarker discovery for TIL therapy using ScaiVision platform |
2023-03-16 |
Tubulis–Occident: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Occident |
2024-03-14 |
Tubulis–Occident: investment, 202205 financing round Series B totalling €60m incl existing + co-investor Occident |
2022-05-03 |
Tubulis–Occident: investment, 202007 financing round Series A totalling €10.7m incl co-investor Occident Group |
2020-07-21 |
Tubulis–Nextech: investment, 202403 financing round Series B2 totalling €128m incl co-lead investor Nextech Invest Ltd |
2024-03-14 |
Tubulis–BioMedPartners: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor BioMedPartners |
2024-03-14 |
Tubulis–BioMedPartners: investment, 202205 financing round Series B totalling €60m incl existing + co-investor BioMedPartners |
2022-05-03 |
Tubulis–BioMedPartners: investment, 202007 financing round Series A totalling €10.7m incl co-lead investor BioMedPartners |
2020-07-21 |
TScan Therapeutics–Novartis: investment, 202101 financing round Series C totalling $100m incl existing investor Novartis Venture Fund |
2021-01-25 |
Tricares–BioMedPartners: investment, 202209 financing round Series C 1st closing totalling €47m incl existing + co-investor BioMed Partners |
2022-09-15 |
TraitGenetics–SGS: investment, 201802 acquisition of TraitGenetics GmbH by SGS |
2018-02-02 |
Topas Therapeutics–BioMedPartners: investment, 202107 financing round Series B extension €18m incl existing investor BioMedPartners |
2021-07-29 |
Topas Therapeutics–BioMedPartners: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor BioMedPartners |
2020-10-19 |
Tolremo Therapeutics–Zürcher Kantonalbank: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing + co-investor ZKB |
2020-06-09 |
Tolremo Therapeutics–Zürcher Kantonalbank: investment, 201809 financing round Series A totalling CHF9m incl exisintg + co-investor ZKB |
2018-09-24 |
Tolremo Therapeutics–SEVERAL: investment, 202006 financing round Series A 2nd closing CHF4.7m bringing total Series A to CHF13.7m |
2020-06-09 |
Tolremo Therapeutics–SEVERAL: investment, 201809 financing round Series A CHF9m led by BioMedPartners |
2018-09-24 |
Tolremo Therapeutics–SEVERAL: investment, 201709 seed financing round CHF2.4m |
2017-09-18 |
Tolremo Therapeutics–Redalpine: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing + co-investor Redalpine VP |
2020-06-09 |
Tolremo Therapeutics–Redalpine: investment, 201809 financing round Series A totalling CHF9m incl new + co-investor Redalpine |
2018-09-24 |
Tolremo Therapeutics–OTHER: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing private biotech investors |
2020-06-09 |
Tolremo Therapeutics–BioMedPartners: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing + co-lead investor BMP |
2020-06-09 |
Tolremo Therapeutics–BioMedPartners: investment, 201809 financing round Series A totalling CHF9m incl new + lead investor BioMedPartners |
2018-09-24 |
Tolremo Therapeutics–Altos Venture: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing + co-lead investor Altos |
2020-06-09 |
Tolremo Therapeutics–Altos Venture: investment, 201809 financing round Series A totalling CHF9m incl new + co-investor Altos Venture |
2018-09-24 |
Tiziana–Novimmune: therapeutic antibody, 201701– license excl €na to develop + commercialise anti-IL-6R MAb NI-1201 |
2017-01-04 |
Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana |
2014-12-01 |
ThromboGenics–Sachs Associates: investor conference, 201709 supply service ThromboGenics presents at Sachs Biotech in Europe Forum in Basel |
2017-09-26 |
ThromboGenics–Novartis: investment, 201709–201801 equity investment €10m by Novartis after termination of Jetrea agreement |
2017-09-18 |
Thermo Fisher–Univ Basel: DNA sequencing, 201704– collab Univ Hospital joins NGS Companion Dx Center of Excellence Program |
2017-04-18 |
Thermo Fisher–Biognosys: mass spectrometry s/w, 201706– collab co-marketing of Spectronaut Pulsar s/w with Orbitrap mass spectrometers |
2017-06-05 |
Therachon–Versant Ventures: investment, 201905 existing investor Versant Ventures |
2019-05-08 |
Therachon–Tekla Capital: investment, 201905 existing investor Tekla Capital Management LLC |
2019-05-08 |
Therachon–Pfizer: investment, 201905–201907 acquisition 100% $340m upfront + $470m milestones excl apraglutide development program |
2019-05-08 |
Therachon–Pfizer: investment, 201905 existing investor Pfizer Ventures |
2019-05-08 |
Therachon–OrbiMed: investment, 201905 existing investor OrbiMed |
2019-05-08 |
Therachon–Novo Group: investment, 201905 existing investor Novo Holdings |
2019-05-08 |
Therachon–France (govt): investment, 201905 existing investors Bpifrance + Inserm Transfert Initiative |
2019-05-08 |
Therachon–Cowen: investment, 201905 existing investor Cowen |
2019-05-08 |
TG Therapeutics–Novimmune: bispecific antibody, 201806– collab + excl license option ww for CD47/CD19 antibody NI-1701 (TG-1801) |
2018-06-20 |
Terns Pharmaceuticals–Samsara Capital: investment, 202101 financing round Series C totalling $87m incl co-investor Samsara Capital |
2021-01-05 |
Teneobio–Selexis: cell line development, 201706– supply service access to SUREtechnology platform to develop cell expression of UniAbs |
2017-06-12 |
Ten23 Health–Bionter: particle counting, 202305– collab developm of methods incl installation of EVE particle counter at Ten23 Heatlh |
2023-05-02 |
TeleClinic–Zur Rose Group: investment, 202007– acquisition of TeleClinic GmbH for mid-double-digit million EUR price by Zur Rose Group |
2020-07-16 |